Of all the chief executives of the world’s major biopharmaceutical companies, the one who could be excused for spending the most sleepless nights so far in 2021 is Michel Vounatsos.
The Biogen (Nasdaq: BIIB) boss has seen his company go through more highs and lows over the past eight months than many drugmakers do in a decade, with the highlights and lowlights including a milestone US Food and Drug Administration (FDA) approval and congressional committees making claims of an unnaturally close relationship between the firm and the agency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze